Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $315.00 | Mkt Perform → Outperform | Raymond James |
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein |
| 10/7/2024 | $402.00 → $261.00 | Buy → Hold | TD Cowen |
| 10/7/2024 | $519.00 → $253.00 | Buy → Hold | Jefferies |
| 10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler |
| 10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities |
Organization Recognized for Seventh Time in Eight Years CenterWell Specialty Pharmacy has once again received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category, its seventh such win in the past eight years. The award recognizes best-in-class customer satisfaction and commitment to patient care by a specialty pharmacy. "There's something so rewarding about seeing our team's dedication to excellent care and support being recognized year after year by the people we serve," said Guillermo Sollberger, senior vice president of CenterWell Specialty Pharmacy and CenterWell Pharmacy. "We know that many of the patients who require specialty drugs are feeling overwhelmed, so
Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident
Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv
Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident
Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv
Humana Inc. (NYSE:HUM) will release financial results for the first quarter 2025 (1Q25) and host a live question-and-answer session on Wednesday, April 30, 2025. Additionally, the company will host an Investor Conference on Monday, June 16, 2025. 1Q25 Earnings Humana will release its 1Q25 financial results, as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on April 30, 2025. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. A webcast of the 1Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gc
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
10-Q - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
4 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)